By: IPP Bureau
Last updated : August 06, 2026 9:29 am
The company posted a 25.2% increase in net profit to Rs 1,032 crore, while EBITDA rose 20% year-on-year to Rs 1,924 crore, with EBITDA margin improving 60 basis points to 21.0%
Aurobindo Pharma Ltd. reported a 16.3% year-on-year increase in consolidated revenue from operations to Rs 9,150 crore for the first quarter ended June 30, 2026, driven by strong growth across its formulations and active pharmaceutical ingredients (API) businesses, particularly in Europe and emerging markets.
The company posted a 25.2% increase in net profit to Rs 1,032 crore, while EBITDA (before forex, other income and exceptional items) rose 20% year-on-year to Rs 1,924 crore, with EBITDA margin improving 60 basis points to 21.0%.
K. Nithyananda Reddy, Vice Chairman and Managing Director, Aurobindo Pharma, said, "We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio. While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long-term growth objectives.”
The United States remained Aurobindo's largest market, with revenue increasing 8.1% year-on-year to Rs 3,770 crore (USD 399 million), supported by new product launches and volume growth.
During the quarter, the company received 10 final approvals from the US Food and Drug Administration (USFDA) and launched 10 new products. As of June 30, 2026, Aurobindo had filed 896 ANDAs with the USFDA and received 737 final approvals and 33 tentative approvals.
Europe emerged as the fastest-growing major market, with revenue rising 25.6% to Rs 2,937 crore (EUR 267 million), driven by strong performance across key countries. Revenue from Growth Markets surged 37.7% to Rs 1,063 crore (USD 113 million), reflecting robust demand across international markets.
The formulations business remained the primary growth engine, with revenue increasing 16.5% year-on-year to Rs 8,101 crore, accounting for the majority of consolidated sales.
The antiretroviral (ARV) business generated revenue of Rs 330 crore (USD 35 million), remaining broadly stable sequentially, with performance influenced by tender opportunities.
Aurobindo maintained a net cash position of USD 42 million as of June 30, 2026, despite completing the USD 247 million acquisition of Lannett and executing a USD 85 million share buyback. The company generated free cash flow of USD 98 million during the quarter, while basic and diluted earnings per share (EPS) stood at Rs 17.86.